Saniona to participate in multiple upcoming virtual investor conferences
October 06 2021 - 7:00AM
Saniona to participate in multiple upcoming virtual investor
conferences
PRESS RELEASE
6 October
2021
Saniona (OMX: SANION), a clinical stage
biopharmaceutical company focused on rare diseases, today
announced that it will present at multiple
upcoming virtual investor conferences this fall. Details are as
follows:
Aktiespararna’s Aktiedagen Stockholm 2021Date/Time: 11 October
2021, 19.00 CEST / 1:00 p.m. EDTPresenter: Trista Morrison, Chief
Communications OfficerWebcast Link:
https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-11-oktober-digitalt-evenemang
BioStock Life Science SummitDate/Time: 20-21, October 2021, time
slot not yet availablePresenter: Rami Levin, President and
CEOWebsite Link: https://www.summit.biostock.se/
Redeye Life Science DayDate/Time: 11 November 2021, time slot
not yet availablePresenter: Rami Levin, President and CEOWebsite
Link:
https://www.redeye.se/events/815899/redeye-life-science-day-2021
Aktieportföljen LiveDate/Time: 24 November 2021, 14.50 CEST /
8:50 a.m. CET/ETPresenter: Trista Morrison, Chief Communications
OfficerWebsite Link: not yet available
EvercoreISI HealthCONX 2021Date/Time: 30 November - 2 December
2021, time slot not yet availablePresenter: Rami Levin, President
and CEOWebsite Link: not yet available
As presenting times and live webcast links become available,
they will be shared on the Saniona website in the Events &
Presentations section:
https://ir.saniona.com/events-and-presentations. Live webcasts will
be available at the links provided. Subsequently, the recorded
webcast events will be archived for approximately 90 days on
Saniona’s website.
For more information, please
contact Trista Morrison, Chief Communications Officer,
Saniona. Office: + 1 (781) 810-9227. Email:
trista.morrison@saniona.com
The information was submitted for publication, through the
agency of the contact person set out above, at 14.00 CEST on 6
October 2021.
About SanionaSaniona is a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing innovative therapies for patients
suffering from rare diseases for which there are a lack of
available treatment options. The company’s lead product candidate,
Tesomet, is in mid-stage clinical trials for hypothalamic obesity
and Prader-Willi syndrome, serious rare disorders characterized by
severe weight gain, disturbances of metabolic functions and
uncontrollable hunger. Saniona has developed a proprietary ion
channel drug discovery engine anchored by IONBASE™, a database of
more than 130,000 ion channel modulators, of which more than 20,000
are Saniona’s proprietary compounds. Through its ion channel
expertise, Saniona is advancing two wholly-owned ion channel
modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical
trial and may be applicable in the treatment of rare neuropathic
disorders, and SAN903 is in preclinical development for rare
inflammatory, fibrotic and hematological disorders. Led by an
experienced scientific and operational team, Saniona has an
established research organization in the Copenhagen area, Denmark,
and a corporate office in the Boston, Massachusetts area, U.S. The
company’s shares are listed on Nasdaq Stockholm Small Cap (OMX:
SANION). Read more at http://www.saniona.com.
- Fall conf press release 10.06.21
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Jan 2025 to Feb 2025
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Feb 2024 to Feb 2025
